A generic sample preparation method for the multiplex analysis of seven therapeutic monoclonal antibodies in human plasma or serum with liquid chromatography-tandem mass spectrometry

A generic sample preparation method for the multiplex analysis of seven therapeutic monoclonal antibodies in human plasma or serum with liquid chromatography-tandem mass spectrometry
Because of the rising variety of therapeutic monoclonal antibodies (mAbs) used within the clinic, there’s an rising want for sturdy analytical strategies to quantify complete mAb concentrations in human plasma for medical research and therapeutic drug monitoring.
We developed a simple, fast, and sturdy pattern preparation methodology for liquid chromatography-tandem mass spectrometry (LC-MS/MS) evaluation. The tactic was validated for infliximab (IFX), rituximab (RTX), cetuximab (CTX), dupilumab (DPL), dinutuximab (DNX), vedolizumab (VDZ), and emicizumab (EMZ). Saturated ammonium sulfate (AS) was used to precipitate immunoglobulins in human plasma.
After centrifugation, supernatant containing albumin was decanted, and the precipitated immunoglobulin fraction was re-dissolved in buffer containing 6M guanidine. This fraction was then utterly denatured, lowered, alkylated, and trypsin digested. Lastly, signature peptides from the seven mAbs had been concurrently quantified on LC-MS/MS along with their inside requirements secure isotopically labeled peptide counterparts.
The linear dynamic ranges (1 – 512 mg/L) of IFX, CTX, RTX, and EMZ confirmed wonderful (R2 > 0.999) linearity and people of DPL, DNX, and VDZ confirmed good (R2 > 0.995) linearity. The tactic was validated in accordance with the EMA tips. EDTA plasma, sodium citrate plasma, heparin plasma, and serum yielded comparable outcomes.
Ready samples had been secure at room temperature (20°C) and at 5°C for three days, and confirmed no decline in focus for all examined mAbs. This described methodology, which has the benefit of a simple, fast, and sturdy pre-analytical pattern preparation, can be utilized as a template to quantify different mAbs in human plasma or serum.

Reactions and COVID-19 illness development following SARS-CoV-2 monoclonal antibody infusion

SARS-CoV-2 monoclonal antibodies (mAbs) have been proposed as a remedy for gentle to average COVID-19, with favorable outcomes reported in medical trials and an emergency use authorization granted by the Meals and Drug Administration. Actual-world knowledge stay restricted, nevertheless, and thus this evaluation presents findings from over 6,500 outpatient administrations of mAb at services affiliated with a big healthcare group in the US.
Inside 48 hours of mAb infusion, 15.6% (1,043) of sufferers obtained a drug that was indicative of a potential response to the infusion; the vast majority of these had been gentle (e.g., acetaminophen). Roughly 5.2% of sufferers who obtained mAb (n=347) had a post-infusion emergency division go to or admission for COVID-19 illness development.
The outcomes of this evaluation point out that sufferers who obtain mAb have a low chance of each an instantaneous detrimental response to the remedy in addition to future inpatient admission associated to COVID-19 illness development.

A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable web site

Potent neutralizing SARS-CoV-2 antibodies typically goal the spike protein receptor-binding web site (RBS), however the variability of RBS epitopes hampers broad neutralization of a number of sarbecoviruses and drifted viruses. Right here, utilizing humanized mice, we recognized an RBS antibody with a germline VH gene that potently neutralized SARS-related coronaviruses, together with SARS-CoV and SARS-CoV-2 variants.
X-ray crystallography revealed coordinated recognition by the heavy chain of non-RBS conserved websites and the sunshine chain of RBS with a binding angle mimicking the angiotensin-converting enzyme 2 (ACE2) receptor. The minimal footprints within the hypervariable area of RBS contributed to the breadth of neutralization, which was enhanced by immunoglobulin G3 (IgG3) class switching.
The coordinated binding resulted in broad neutralization of SARS-CoV and rising SARS-CoV-2 variants of concern. Low-dose therapeutic antibody remedy in hamsters lowered the virus titers and morbidity throughout SARS-CoV-2 problem. The structural foundation for broad neutralizing exercise could inform the design of a broad spectrum of therapeutics and vaccines.

Pharmacodynamic measures inside tumors expose differential exercise of PD(L)-1 antibody therapeutics

Macromolecules reminiscent of monoclonal antibodies (mAbs) are prone to expertise poor tumor penetration due to their massive dimension, and thus low drug publicity of goal cells inside a tumor might contribute to suboptimal responses. Given the problem of insufficient quantitative instruments to evaluate mAb exercise inside tumors, we hypothesized that measurement of accessible goal ranges in tumors might elucidate the pharmacologic exercise of a mAb and might be used to match the exercise of various mAbs.
Utilizing positron emission tomography (PET), we measured the pharmacodynamics of immune checkpoint protein programmed-death ligand 1 (PD-L1) to guage pharmacologic results of mAbs concentrating on PD-L1 and its receptor programmed cell demise protein 1 (PD-1). For PD-L1 quantification, we first developed a small peptide-based fluorine-18-labeled PET imaging agent, [18F]DK222, which supplied high-contrast pictures in preclinical fashions.
We then quantified accessible PD-L1 ranges within the tumor mattress throughout remedy with anti-PD-1 and anti-PD-L1 mAbs. Making use of mixed-effects fashions to those knowledge, we discovered delicate variations within the pharmacodynamic results of two anti-PD-1 mAbs (nivolumab and pembrolizumab).
In distinction, we noticed starkly divergent goal engagement with anti-PD-L1 mAbs (atezolizumab, avelumab, and durvalumab) that had been administered at equal doses, correlating with differential results on tumor development. Thus, we present that measuring PD-L1 pharmacodynamics informs mechanistic understanding of therapeutic mAbs concentrating on PD-L1 and PD-1.
These findings exhibit the worth of quantifying goal pharmacodynamics to elucidate the pharmacologic exercise of mAbs, unbiased of mAb biophysical properties and inclusive of all physiological variables, that are extremely heterogeneous inside and throughout tumors and sufferers.

Ehrlichia chaffeensis and E. canis hypothetical protein immunoanalysis reveals small secreted immunodominant proteins and conformation-dependent antibody epitopes

Immunomolecular characterization of Ehrlichia chaffeensis (E. ch.) and E. canis (E. ca.) has outlined protein orthologs, together with tandem repeat proteins (TRPs) which have immunodominant linear antibody epitopes. On this examine, we mixed bioinformatic evaluation and cell-free protein expression to determine undiscovered immunoreactive E. ch. and E. ca. hypothetical proteins.
Antigenicity of the E. ch. and E. ca. ORFeomes (n = 1105 and n = 925, respectively) was analyzed by the sequence-based prediction mannequin ANTIGENpro, and we recognized ~250 ORFs in every respective ORFeome as extremely antigenic. The hypothetical proteins (E. ch. n = 93 and E. ca. n = 98) current within the prime 250 antigenic ORFs had been additional investigated on this examine. By ELISA, 46 E. ch. and 30 E. ca.
IVTT-expressed hypothetical proteins reacted with antibodies in sera from naturally E. ch.-infected sufferers or E. ca.-infected canine. Furthermore, 15 E. ch. and 16 E. ca. proteins persistently reacted with a panel of sera from sufferers or canine, together with many that exposed the immunoreactivity of “gold commonplace” TRPs. Antibody epitopes in most (>70%) of those proteins exhibited partial or full conformation-dependence.

Cytokeratin 14 (Cytokeratin 14) Antibody

20-abx009056
  • EUR 300.00
  • EUR 439.00
  • EUR 189.00
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 8 (Cytokeratin 8) Antibody

20-abx009059
  • EUR 300.00
  • EUR 439.00
  • EUR 189.00
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 7 (Cytokeratin 7) Antibody

20-abx009060
  • EUR 300.00
  • EUR 439.00
  • EUR 189.00
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 15 (Cytokeratin 15) Antibody

20-abx225265
  • EUR 370.00
  • EUR 606.00
  • EUR 314.00
  • 100 ul
  • 200 ul
  • 50 ul

Cytokeratin 14 (Cytokeratin 14) Antibody

abx232195-100ug 100 ug
EUR 481

Cytokeratin 14 (Cytokeratin 14) Antibody

abx232196-100ug 100 ug
EUR 509

Cytokeratin 14 (Cytokeratin 14) Antibody

abx232197-100ug 100 ug
EUR 551

Cytokeratin 15 (Cytokeratin 15) Antibody

abx232198-100ug 100 ug
EUR 481

Cytokeratin 15 (Cytokeratin 15) Antibody

abx232199-100ug 100 ug
EUR 509

Cytokeratin 4 (Cytokeratin 4) Antibody

abx232214-100ug 100 ug
EUR 481

Cytokeratin 7 (Cytokeratin 7) Antibody

abx232217-100ug 100 ug
EUR 509

Cytokeratin 7 (Cytokeratin 7) Antibody

abx232218-100ug 100 ug
EUR 551

Cytokeratin 8 (Cytokeratin 8) Antibody

abx232221-100ug 100 ug
EUR 481

Cytokeratin 8 (Cytokeratin 8) Antibody

abx232222-100ug 100 ug
EUR 551

Cytokeratin 8 (Cytokeratin 8) Antibody

abx232223-100ug 100 ug
EUR 551

Cytokeratin 8 (Cytokeratin 8) Antibody

abx139677-01mg 0.1 mg
EUR 356

Cytokeratin 8 (Cytokeratin 8) Antibody

abx139678-01mg 0.1 mg
EUR 356

Cytokeratin 8 (Cytokeratin 8) Antibody (FITC)

abx139679-01mg 0.1 mg
EUR 425

Cytokeratin antibody

20R-CP006 100 uL
EUR 459
Description: Guinea Pig polyclonal Cytokeratin antibody

Cytokeratin antibody

10R-6655 100 ug
EUR 521
Description: Mouse monoclonal Cytokeratin antibody

Cytokeratin antibody

10R-6656 100 ug
EUR 521
Description: Mouse monoclonal Cytokeratin antibody

Cytokeratin 5 antibody

70R-35563 100 ug
EUR 349
Description: Purified Rabbit polyclonal Cytokeratin 5 antibody

Cytokeratin 1 antibody

70R-4604 50 ug
EUR 467
Description: Rabbit polyclonal Cytokeratin 1 antibody

Cytokeratin 5 antibody

70R-49975 100 ul
EUR 244
Description: Purified Polyclonal Cytokeratin 5 antibody

Cytokeratin 7 antibody

70R-49976 100 ul
EUR 244
Description: Purified Polyclonal Cytokeratin 7 antibody

Cytokeratin 8 antibody

70R-49977 100 ul
EUR 287
Description: Purified Polyclonal Cytokeratin 8 antibody

Cytokeratin 8 antibody

70R-49978 100 ul
EUR 244
Description: Purified Polyclonal Cytokeratin 8 antibody

Cytokeratin 10 antibody

70R-49979 100 ul
EUR 244
Description: Purified Polyclonal Cytokeratin 10 antibody

Cytokeratin 13 antibody

70R-49980 100 ul
EUR 244
Description: Purified Polyclonal Cytokeratin 13 antibody

Cytokeratin 14 antibody

70R-49981 100 ul
EUR 244
Description: Purified Polyclonal Cytokeratin 14 antibody

Cytokeratin 16 antibody

70R-49982 100 ul
EUR 244
Description: Purified Polyclonal Cytokeratin 16 antibody

Cytokeratin 17 antibody

70R-49983 100 ul
EUR 244
Description: Purified Polyclonal Cytokeratin 17 antibody

Cytokeratin 18 antibody

70R-49984 100 ul
EUR 287
Description: Purified Polyclonal Cytokeratin 18 antibody

Cytokeratin 18 antibody

70R-49985 100 ul
EUR 244
Description: Purified Polyclonal Cytokeratin 18 antibody

Cytokeratin 19 antibody

70R-49986 100 ul
EUR 244
Description: Purified Polyclonal Cytokeratin 19 antibody

Cytokeratin 19 antibody

70R-49987 100 ul
EUR 244
Description: Purified Polyclonal Cytokeratin 19 antibody

Cytokeratin 84 antibody

70R-49988 100 ul
EUR 244
Description: Purified Polyclonal Cytokeratin 84 antibody

Cytokeratin 8 antibody

70R-51570 100 ul
EUR 244
Description: Purified Polyclonal Cytokeratin 8 antibody

Cytokeratin 8 antibody

70R-51571 100 ul
EUR 244
Description: Purified Polyclonal Cytokeratin 8 antibody

Cytokeratin 18 antibody

70R-51572 100 ul
EUR 287
Description: Purified Polyclonal Cytokeratin 18 antibody

Cytokeratin 18 antibody

70R-51573 100 ul
EUR 244
Description: Purified Polyclonal Cytokeratin 18 antibody

Cytokeratin 17 antibody

70R-3229 50 ug
EUR 467
Description: Rabbit polyclonal Cytokeratin 17 antibody raised against the C terminal of KRT17

Cytokeratin 8 antibody

70R-3263 50 ug
EUR 467
Description: Rabbit polyclonal Cytokeratin 8 antibody raised against the middle region of KRT8

Cytokeratin 8 antibody

70R-3292 50 ug
EUR 467
Description: Rabbit polyclonal Cytokeratin 8 antibody raised against the N terminal of KRT8

Cytokeratin 18 antibody

70R-33530 100 ug
EUR 327
Description: Rabbit polyclonal Cytokeratin 18 antibody

Cytokeratin 8 antibody

70R-33532 100 ug
EUR 327
Description: Rabbit polyclonal Cytokeratin 8 antibody

Cytokeratin 13 Antibody

AF5102 200ul
EUR 304
Description: Cytokeratin 13 Antibody detects endogenous levels of total Cytokeratin 13.

Cytokeratin 19 Antibody

AF5106 200ul
EUR 304
Description: Cytokeratin 19 Antibody detects endogenous levels of total Cytokeratin 19.

Cytokeratin 5 Antibody

BF0108 200ul
EUR 376
Description: Cytokeratin 5 antibody detects endogenous levels of total Cytokeratin 5.

Cytokeratin 19 Antibody

BF0197 200ul
EUR 376
Description: Cytokeratin 19 antibody detects endogenous levels of total Cytokeratin 19.

Cytokeratin 8 Antibody

BF0606 200ul
EUR 376
Description: Cytokeratin 8 antibody detects endogenous levels of total Cytokeratin 8.

Cytokeratin 18 antibody

BF0727 200ul
EUR 376
Description: Cytokeratin 18 mouse monoclonal antibody detects endogenous levels of total CK18.

Cytokeratin 19 Antibody

ABD2916 100 ug
EUR 438

Cytokeratin?13 Antibody

ABF5102 100 ug
EUR 438

Cytokeratin?19 Antibody

ABF5106 100 ug
EUR 438

anti-Cytokeratin 4

YF-PA12870 50 ul
EUR 363
Description: Mouse polyclonal to Cytokeratin 4

anti-Cytokeratin 4

YF-PA12871 100 ug
EUR 403
Description: Rabbit polyclonal to Cytokeratin 4

anti-Cytokeratin 5

YF-PA12872 100 ug
EUR 403
Description: Rabbit polyclonal to Cytokeratin 5

anti-Cytokeratin 7

YF-PA12874 50 ug
EUR 363
Description: Mouse polyclonal to Cytokeratin 7

anti-Cytokeratin 7

YF-PA12875 100 ug
EUR 403
Description: Rabbit polyclonal to Cytokeratin 7

anti-Cytokeratin 8

YF-PA12876 50 ul
EUR 363
Description: Mouse polyclonal to Cytokeratin 8

anti-Cytokeratin 8

YF-PA12877 50 ug
EUR 363
Description: Mouse polyclonal to Cytokeratin 8

anti-Cytokeratin 8

YF-PA12878 50 ul
EUR 363
Description: Mouse polyclonal to Cytokeratin 8

anti-Cytokeratin 8

YF-PA12879 50 ug
EUR 363
Description: Mouse polyclonal to Cytokeratin 8

anti-Cytokeratin 8

YF-PA12880 100 ul
EUR 403
Description: Rabbit polyclonal to Cytokeratin 8

anti-Cytokeratin 8

YF-PA12881 100 ug
EUR 403
Description: Rabbit polyclonal to Cytokeratin 8

anti-Cytokeratin 14

YF-PA12883 50 ug
EUR 363
Description: Mouse polyclonal to Cytokeratin 14

anti-Cytokeratin 14

YF-PA12884 100 ug
EUR 403
Description: Rabbit polyclonal to Cytokeratin 14

anti-Cytokeratin 15

YF-PA12886 100 ul
EUR 403
Description: Rabbit polyclonal to Cytokeratin 15

anti-Cytokeratin 15

YF-PA12887 100 ug
EUR 403
Description: Rabbit polyclonal to Cytokeratin 15

anti-Cytokeratin 16

YF-PA12888 50 ul
EUR 363
Description: Mouse polyclonal to Cytokeratin 16

anti-Cytokeratin 16

YF-PA12889 100 ug
EUR 403
Description: Rabbit polyclonal to Cytokeratin 16

anti-Cytokeratin 17

YF-PA12890 50 ul
EUR 363
Description: Mouse polyclonal to Cytokeratin 17

anti-Cytokeratin 17

YF-PA12891 100 ug
EUR 403
Description: Rabbit polyclonal to Cytokeratin 17

anti-Cytokeratin 18

YF-PA12892 50 ul
EUR 363
Description: Mouse polyclonal to Cytokeratin 18

anti-Cytokeratin 18

YF-PA12893 100 ug
EUR 403
Description: Rabbit polyclonal to Cytokeratin 18

anti-Cytokeratin 19

YF-PA12894 50 ug
EUR 363
Description: Mouse polyclonal to Cytokeratin 19

anti-Cytokeratin 19

YF-PA12895 50 ug
EUR 363
Description: Mouse polyclonal to Cytokeratin 19

anti-Cytokeratin 19

YF-PA12896 100 ug
EUR 403
Description: Rabbit polyclonal to Cytokeratin 19

anti-Cytokeratin 34

YF-PA12899 50 ug
EUR 363
Description: Mouse polyclonal to Cytokeratin 34

anti-Cytokeratin 34

YF-PA12900 100 ul
EUR 403
Description: Rabbit polyclonal to Cytokeratin 34

anti-Cytokeratin 34

YF-PA12901 100 ug
EUR 403
Description: Rabbit polyclonal to Cytokeratin 34

anti-Cytokeratin 2

YF-PA18999 50 ul
EUR 363
Description: Mouse polyclonal to Cytokeratin 2

anti-Cytokeratin 2

YF-PA19000 50 ug
EUR 363
Description: Mouse polyclonal to Cytokeratin 2

anti-Cytokeratin 20

YF-PA19307 50 ul
EUR 363
Description: Mouse polyclonal to Cytokeratin 20

anti-Cytokeratin 20

YF-PA19308 50 ug
EUR 363
Description: Mouse polyclonal to Cytokeratin 20

anti-Cytokeratin 20

YF-PA19309 100 ul
EUR 403
Description: Rabbit polyclonal to Cytokeratin 20

anti-Cytokeratin 20

YF-PA19310 100 ug
EUR 403
Description: Rabbit polyclonal to Cytokeratin 20

anti-Cytokeratin 4

YF-PA24059 50 ul
EUR 334
Description: Mouse polyclonal to Cytokeratin 4

anti-Cytokeratin 8

YF-PA24060 50 ul
EUR 334
Description: Mouse polyclonal to Cytokeratin 8

anti-Cytokeratin 16

YF-PA24061 50 ul
EUR 334
Description: Mouse polyclonal to Cytokeratin 16

anti-Cytokeratin 18

YF-PA24062 50 ul
EUR 334
Description: Mouse polyclonal to Cytokeratin 18

anti-Cytokeratin 18

YF-PA25730 50 ul
EUR 334
Description: Mouse polyclonal to Cytokeratin 18

Cytokeratin 18 protein

30R-AC039 250 ug
EUR 681
Description: Purified recombinant Human Cytokeratin 18 protein

Cytokeratin 19 protein

30R-AC040 100 ug
EUR 413
Description: Purified recombinant Human Cytokeratin 19 protein

Cytokeratin 8 protein

30R-AC041 100 ug
EUR 418
Description: Purified recombinant Human Cytokeratin 8 protein

Cytokeratin 14 antibody

20R-CP002 100 ul
EUR 564
Description: Guinea Pig polyclonal Cytokeratin 14 antibody

Cytokeratin 5 antibody

20R-CP003 100 uL
EUR 545
Description: Guinea Pig polyclonal Cytokeratin 5 antibody

Cytokeratin 13 antibody

70R-1178 100 ug
EUR 377
Description: Rabbit polyclonal Cytokeratin 13 antibody raised against the C terminal of KRT13

Cytokeratin 20 antibody

70R-1189 100 ug
EUR 377
Description: Rabbit polyclonal Cytokeratin 20 antibody raised against the middle region of KRT20

Cytokeratin 2 antibody

70R-12684 100 ul
EUR 457
Description: Affinity purified Rabbit polyclonal Cytokeratin 2 antibody

Cytokeratin 10 antibody

70R-13235 100 ul
EUR 430
Description: Affinity purified Rabbit polyclonal Cytokeratin 10 antibody

Cytokeratin 13 antibody

70R-13317 100 ul
EUR 457
Description: Affinity purified Rabbit polyclonal Cytokeratin 13 antibody

Cytokeratin 20 antibody

70R-13379 100 ul
EUR 457
Description: Affinity purified Rabbit polyclonal Cytokeratin 20 antibody

Cytokeratin 34 antibody

70R-13483 100 ul
EUR 457
Description: Affinity purified Rabbit polyclonal Cytokeratin 34 antibody

Cytokeratin 31 antibody

70R-13495 100 ul
EUR 457
Description: Affinity purified Rabbit polyclonal Cytokeratin 31 antibody

Cytokeratin 10 antibody

70R-2225 50 ug
EUR 467
Description: Rabbit polyclonal Cytokeratin 10 antibody

Cytokeratin 13 antibody

70R-2265 50 ug
EUR 467
Description: Rabbit polyclonal Cytokeratin 13 antibody raised against the N terminal of KRT13

Cytokeratin 16 antibody

70R-2869 50 ug
EUR 467
Description: Rabbit polyclonal Cytokeratin 16 antibody

Cytokeratin 16 antibody

70R-2870 50 ug
EUR 467
Description: Rabbit polyclonal Cytokeratin 16 antibody

Cytokeratin 7 antibody

70R-2930 50 ug
EUR 467
Description: Rabbit polyclonal Cytokeratin 7 antibody raised against the N terminal of KRT7

Cytokeratin 19 antibody

70R-2947 50 ug
EUR 467
Description: Rabbit polyclonal Cytokeratin 19 antibody raised against the N terminal of KRT19

Cytokeratin 23 antibody

70R-2948 50 ug
EUR 467
Description: Rabbit polyclonal Cytokeratin 23 antibody

Cytokeratin 24 antibody

70R-2986 50 ug
EUR 467
Description: Rabbit polyclonal Cytokeratin 24 antibody raised against the middle region of KRT24

Cytokeratin 84 antibody

70R-3002 50 ug
EUR 467
Description: Rabbit polyclonal Cytokeratin 84 antibody raised against the middle region of KRT84

Cytokeratin 19 antibody

70R-3035 50 ug
EUR 467
Description: Rabbit polyclonal Cytokeratin 19 antibody raised against the N terminal of KRT19

Cytokeratin 75 antibody

70R-3038 50 ug
EUR 467
Description: Rabbit polyclonal Cytokeratin 75 antibody raised against the N terminal of KRT75

Cytokeratin 75 antibody

70R-3039 50 ug
EUR 467
Description: Rabbit polyclonal Cytokeratin 75 antibody raised against the middle region of KRT75

Cytokeratin 8 antibody

70R-13833 100 ug
EUR 322
Description: Affinity purified Rabbit polyclonal Cytokeratin 8 antibody

Cytokeratin 19 antibody

70R-13877 100 ug
EUR 322
Description: Affinity purified Rabbit polyclonal Cytokeratin 19 antibody

Cytokeratin 18 antibody

70R-1405 100 ug
EUR 377
Description: Rabbit polyclonal Cytokeratin 18 antibody raised against the C terminal of KRT18

Cytokeratin 18 antibody

70R-1474 100 ug
EUR 377
Description: Rabbit polyclonal Cytokeratin 18 antibody raised against the N terminal of KRT18

Cytokeratin 7 antibody

10R-1826 100 ul
EUR 403
Description: Mouse monoclonal CK7 antibody

pan Cytokeratin antibody

10R-2060 100 ul
EUR 403
Description: Mouse monoclonal pan Cytokeratin antibody

Cytokeratin Pan antibody

10R-2096 100 ul
EUR 403
Description: Mouse monoclonal Cytokeratin Pan antibody

Cytokeratin 8 antibody

10R-2766 100 ul
EUR 370
Description: Mouse monoclonal Cytokeratin 8 antibody

Cytokeratin 20 antibody

10R-C164a 50 ug
EUR 575
Description: Mouse monoclonal Cytokeratin 20 antibody

Cytokeratin 20 antibody

10R-C164b 50 ug
EUR 624
Description: Mouse monoclonal Cytokeratin 20 antibody

Cytokeratin 20 antibody

10R-C164c 50 ug
EUR 1011
Description: Mouse monoclonal Cytokeratin 20 antibody

Cytokeratin 2e antibody

10R-C166a 1 mL
EUR 269
Description: Mouse monoclonal Cytokeratin 2e antibody

Cytokeratin 4 antibody

10R-C169a 1 ml
EUR 537
Description: Mouse monoclonal Cytokeratin 4 antibody

Cytokeratin 6 antibody

10R-C172a 50 ug
EUR 445
Description: Mouse monoclonal Cytokeratin 6 antibody

Cytokeratin 6 antibody

10R-C172b 5 mL
EUR 285
Description: Mouse monoclonal Cytokeratin 6 antibody

Cytokeratin 7 antibody

10R-C174a 50 ug
EUR 445
Description: Mouse monoclonal Cytokeratin 7 antibody

Cytokeratin 8 antibody

10R-C177a 5 mL
EUR 346
Description: Mouse monoclonal Cytokeratin 8 antibody

Cytokeratin 8 antibody

10R-C177ax 50 ug
EUR 493
Description: Mouse monoclonal Cytokeratin 8 antibody

Cytokeratin 2 antibody

10R-C179a 50 ug
EUR 445
Description: Mouse monoclonal Cytokeratin 2 antibody

Cytokeratin 9 antibody

10R-C196A 1 mL
EUR 459
Description: Mouse monoclonal Cytokeratin 9 antibody

Cytokeratin 19 antibody

10-1210 500 ug
EUR 435
Description: Mouse monoclonal Cytokeratin 19 antibody

Cytokeratin 19 antibody

10R-6759 1 ml
EUR 402
Description: Mouse monoclonal Cytokeratin 19 antibody

Cytokeratin 18 antibody

10R-6766 1 ml
EUR 402
Description: Mouse monoclonal Cytokeratin 18 antibody

Cytokeratin AE1 antibody

10R-6767 1 ml
EUR 424
Description: Mouse monoclonal Cytokeratin AE1 antibody

Cytokeratin AE3 antibody

10R-6768 1 ml
EUR 411
Description: Mouse monoclonal Cytokeratin AE3 antibody

Cytokeratin antibody cocktail

10R-6769 1 ml
EUR 560
Description: Mouse monoclonal Cytokeratin antibody cocktail
The bulk (23/31; 74%) of the most important immunoreactive proteins recognized had been small (≤250 aa), and 20/31 (65%) had been predicted to be secreted effectors. Not like the robust linear antibody epitopes beforehand recognized in TRP and OMP orthologs, there have been contrasting variations within the E. ch. and E. ca. antigenic repertoires, epitopes and ortholog immunoreactivity. This examine reveals quite a few beforehand undefined immunodominant and subdominant antigens, and illustrates the breadth, complexity, and variety of immunoreactive proteins/epitopes in Ehrlichia.
Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Leave a Reply

Your email address will not be published.

Related Post